Drug Discovery

Protein-Structure Evidence in Target and Candidate Decisions

Published 2026-08-22 · Updated 2026-08-22

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

which structural observation is decision-relevant rather than merely visually persuasive

Why the problem is difficult

The article-specific identification challenge is whether the question “which structural observation is decision-relevant rather than merely visually persuasive” can be resolved using experimental method, resolution, conformational state, construct, ligands, predicted regions, and dynamics, rather than merely restated in new language.

A falsifier-first workflow

• Define the decision precisely: which structural observation is decision-relevant rather than merely visually persuasive.
• Build a source and data ledger around experimental method, resolution, conformational state, construct, ligands, predicted regions, and dynamics.
• Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
• Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
• Run the lowest-cost discriminating challenge: test whether the claimed interaction persists across plausible conformations and structures.
• Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

• Decision impact: would the result materially change the choice about which structural observation is decision-relevant rather than merely visually persuasive?
• Evidence fit: does the available evidence—experimental method, resolution, conformational state, construct, ligands, predicted regions, and dynamics—directly address the decision rather than merely correlate with it?
• Discrimination: does the preferred route predict an outcome a credible alternative does not?
• Robustness: does the ranking survive the challenge “test whether the claimed interaction persists across plausible conformations and structures”?
• Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

experimental method, resolution, conformational state, construct, ligands, predicted regions, and dynamics

Counterevidence

For this decision, a result from “test whether the claimed interaction persists across plausible conformations and structures” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about which structural observation is decision-relevant rather than merely visually persuasive or exposes why the available evidence cannot resolve it.

Fastest falsifier

test whether the claimed interaction persists across plausible conformations and structures

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “test whether the claimed interaction persists across plausible conformations and structures” without an independently supported alternative mechanism.

Evidence ceiling

A static or predicted structure does not establish binding, function, selectivity, or cellular effect.

Sources and starting points

• Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
• ChEMBL — Curated bioactivity information for compounds, assays, and targets.
• ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
• PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
• PubChem — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
• FDA Drug Development and Approval Process — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

1. Drug Target Prioritization: A Falsifier-First Framework
2. Target Identification vs Target Validation in Drug Discovery
3. What Counts as Evidence for Drug Target Validation?
4. Map the Translational Gap Before Advancing a Drug Program

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “Protein-Structure Evidence in Target and Candidate Decisions” help make?

It supports a bounded decision about which structural observation is decision-relevant rather than merely visually persuasive. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.

What is the fastest useful test?

test whether the claimed interaction persists across plausible conformations and structures

Can computation validate the final scientific claim?

No. A static or predicted structure does not establish binding, function, selectivity, or cellular effect. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.

When should the project stop or reframe?

Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.